MA39819A - Méthodes et compositions d'immunomodulation - Google Patents

Méthodes et compositions d'immunomodulation

Info

Publication number
MA39819A
MA39819A MA039819A MA39819A MA39819A MA 39819 A MA39819 A MA 39819A MA 039819 A MA039819 A MA 039819A MA 39819 A MA39819 A MA 39819A MA 39819 A MA39819 A MA 39819A
Authority
MA
Morocco
Prior art keywords
immunomodulation
compositions
methods
cells containing
exogenous antigen
Prior art date
Application number
MA039819A
Other languages
English (en)
Inventor
Noubar B Afeyan
Avak Kahvejian
Jordi Mata-Fink
John Round
Original Assignee
Rubius Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/065304 external-priority patent/WO2015073587A2/fr
Application filed by Rubius Therapeutics Inc filed Critical Rubius Therapeutics Inc
Publication of MA39819A publication Critical patent/MA39819A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)

Abstract

L'invention concerne des cellules contenant un antigène exogène et les utilisations de celles-ci.
MA039819A 2014-04-01 2015-03-13 Méthodes et compositions d'immunomodulation MA39819A (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201461973764P 2014-04-01 2014-04-01
US201461973763P 2014-04-01 2014-04-01
US201461991319P 2014-05-09 2014-05-09
US201462006832P 2014-06-02 2014-06-02
US201462006825P 2014-06-02 2014-06-02
US201462006828P 2014-06-02 2014-06-02
US201462006829P 2014-06-02 2014-06-02
US201462025367P 2014-07-16 2014-07-16
US201462059100P 2014-10-02 2014-10-02
PCT/US2014/065304 WO2015073587A2 (fr) 2013-11-18 2014-11-12 Complexes membrane synthétique- récepteur

Publications (1)

Publication Number Publication Date
MA39819A true MA39819A (fr) 2017-02-08

Family

ID=54241093

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039819A MA39819A (fr) 2014-04-01 2015-03-13 Méthodes et compositions d'immunomodulation

Country Status (18)

Country Link
US (4) US10869898B2 (fr)
EP (2) EP3125927B1 (fr)
JP (4) JP6735233B2 (fr)
KR (2) KR20170005801A (fr)
CN (1) CN106456744A (fr)
AU (3) AU2015241422B2 (fr)
BR (1) BR112016022814A8 (fr)
CA (1) CA2944492A1 (fr)
DK (1) DK3125927T3 (fr)
ES (1) ES2865825T3 (fr)
HU (1) HUE054471T2 (fr)
IL (3) IL248143B (fr)
MA (1) MA39819A (fr)
MX (1) MX2020000621A (fr)
PL (1) PL3125927T3 (fr)
PT (1) PT3125927T (fr)
RU (2) RU2020136119A (fr)
WO (1) WO2015153102A1 (fr)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2013059343A1 (fr) 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Administration intracellulaire
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US10124336B2 (en) 2013-08-16 2018-11-13 Massachusetts Institute Of Technology Selective delivery of material to cells
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
CA2946064C (fr) 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Agents therapeutiques de glycociblage
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
CN122564053A (zh) 2014-10-31 2026-08-14 麻省理工学院 递送生物分子至免疫细胞
WO2016077761A1 (fr) 2014-11-14 2016-05-19 Massachusetts Institute Of Technology Acheminement de composés et de compositions dans des cellules activé par des perturbations et un champ
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
US20230302051A1 (en) * 2015-02-27 2023-09-28 Icell Gene Therapeutics Inc. CHIMERIC ANTIGEN RECEPTORS (CARs), TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOF
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
JP6925984B2 (ja) 2015-07-09 2021-08-25 マサチューセッツ インスティテュート オブ テクノロジー 無核細胞への物質の送達
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
RU2766177C2 (ru) * 2015-10-14 2022-02-08 Мегакарион Корпорейшн Способ получения очищенных тромбоцитов
CN108697733A (zh) 2016-01-11 2018-10-23 鲁比厄斯治疗法股份有限公司 与癌症适应症的多模式治疗性细胞体系有关的组合物和方法
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
MX2019000205A (es) * 2016-07-07 2019-09-23 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
SG11201901393VA (en) * 2016-09-02 2019-03-28 Univ Illinois Kif13b-derived peptide and method of inhibiting angiogenesis
EP3529347A1 (fr) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Extraction par affinité de cellules par un procédé acoustique
BR112019011138A2 (pt) * 2016-12-02 2019-10-01 Rubius Therapeutics, Inc. composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos
WO2018144966A1 (fr) * 2017-02-06 2018-08-09 The Board Of Trustees Of The Leland Stanford Junior University Procédés de bioconjugaison pour une administration thérapeutique in situ ciblée
CN110520522A (zh) * 2017-02-17 2019-11-29 鲁比厄斯治疗法股份有限公司 功能化红系细胞
EP3595681A4 (fr) 2017-03-16 2020-12-16 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Immunothérapie à base de cellules pouvant être greffées pour l'administration sur une longue période de protéines thérapeutiques
EP3638296A1 (fr) 2017-06-16 2020-04-22 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
WO2019017937A1 (fr) 2017-07-19 2019-01-24 Rubius Therapeutics, Inc. Compositions et méthodes associées à des systèmes cellulaires thérapeutiques multimodaux pour le traitement d'une maladie cardiométabolique
WO2019017940A1 (fr) 2017-07-19 2019-01-24 Rubius Therapeutics, Inc. Compositions et méthodes associées à des systèmes cellulaires thérapeutiques multimodaux pour le traitement d'une maladie infectieuse
SG11202000820PA (en) * 2017-07-31 2020-02-27 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2019032628A1 (fr) * 2017-08-07 2019-02-14 The Regents Of The University Of California Plate-forme de génération d'agents thérapeutiques cellulaires sans risque
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
EP3672602A1 (fr) 2017-08-22 2020-07-01 Rubius Therapeutics, Inc. Procédés et compositions de nanoparticules lipidiques destinés à la production de cellules érythroïdes modifiées
CN107510839A (zh) * 2017-08-31 2017-12-26 广东颜值科技有限公司 一种免疫调节剂及其制备方法和应用
EP3700334B1 (fr) 2017-10-27 2026-04-08 Immunebridge Inc. Compositions et procédés de production de cellules souches hématopoïétiques expansées mettant en oeuvre des dérivés de fluorène
WO2019090148A2 (fr) 2017-11-03 2019-05-09 Rubius Therapeutics, Inc. Compositions et procédés associés à des systèmes cellulaires thérapeutiques pour inhiber la croissance tumorale
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
CA3084674A1 (fr) 2017-12-23 2019-06-27 Rubius Therapeutics, Inc. Cellules artificielles presentatrices d'antigenes et methodes d'utilisation
US20190201548A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for engineering erythroid cells
CA3087344A1 (fr) 2018-01-05 2019-07-11 Platelet Biogenesis, Inc. Compositions et procedes pour produire des megacaryocytes
WO2019140116A2 (fr) 2018-01-10 2019-07-18 Rubius Therapeutics, Inc. Arn amplifiables pour systèmes cellulaires thérapeutiques
WO2019165183A1 (fr) * 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions et méthodes de traitement de l'encéphalopathie mitochondriale neurogastro-intestinale
SG11202008261WA (en) 2018-03-08 2020-09-29 Rubius Therapeutics Inc Therapeutic cell systems and methods for treating cancer and infectious diseases
US20190309269A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating hyperuricemia and gout
US20190309271A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating homocystinuria
EP3790577A4 (fr) 2018-05-09 2022-04-27 The University of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
CN112118859A (zh) * 2018-05-16 2020-12-22 杰特有限公司 1型可溶性补体受体变体及其用途
JP2021529770A (ja) 2018-06-29 2021-11-04 プレートレット バイオジェネシス, インコーポレイテッド 薬物送達のための組成物およびその使用方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020117852A1 (fr) 2018-12-03 2020-06-11 Rubius Therapeutics, Inc. Cellules présentatrices d'antigène artificielles comprenant des molécules hla-e et hla-g et procédés d'utilisation
MX2021006930A (es) * 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
CA3121528A1 (fr) 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes et methodes d'utilisation
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
IL284878B2 (en) 2019-01-18 2026-04-01 Flagship Pioneering Inc TREM preparations and their uses
CN109810992A (zh) * 2019-02-01 2019-05-28 天津师范大学 一种编码牙鲆胞外ATP水解酶CD39的cDNA全长序列及其应用
JP2022521738A (ja) 2019-02-20 2022-04-12 ルビウス セラピューティクス, インコーポレイテッド 負荷可能な抗原提示ポリペプチドを含む操作された赤血球系細胞および使用方法
CN121081491A (zh) 2019-03-04 2025-12-09 旗舰创业创新第六有限责任公司 环状多核糖核苷酸及其药物组合物
JP7618577B2 (ja) 2019-03-25 2025-01-21 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 修飾環状ポリリボヌクレオチドを含む組成物及びその使用
JP2022530130A (ja) * 2019-04-26 2022-06-27 ルビウス セラピューティクス, インコーポレイテッド 除核赤血球細胞を含む緩衝組成物
CN110244053B (zh) * 2019-05-09 2022-03-11 北京大学第三医院(北京大学第三临床医学院) 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途
JP2022534988A (ja) 2019-05-31 2022-08-04 フラッグシップ パイオニアリング, インコーポレイテッド tRNAプールを調節するためのTREMの使用
CN110215737B (zh) * 2019-06-13 2021-07-02 厦门华厦学院 一种基于石墨烯-纳米金复合界面超高负载核酸适配体的亲和整体柱及其制备方法
US20220257794A1 (en) 2019-06-14 2022-08-18 Flagship Pioneering Innovations Vi, Llc Circular rnas for cellular therapy
US12636369B2 (en) 2019-06-19 2026-05-26 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
MX2021015966A (es) 2019-06-26 2022-04-06 Travere Therapeutics Switzerland Gmbh Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria.
AR119906A1 (es) 2019-09-05 2022-01-19 Hemanext Inc Métodos para la conservación de glóbulos rojos reactivos utilizando monóxido de carbono
WO2021092073A1 (fr) 2019-11-04 2021-05-14 Flagship Pioneering, Inc. Procédés de modification d'une séquence d'acide nucléique
CA3160097A1 (fr) 2019-11-04 2021-05-14 Flagship Pioneering, Inc. Compositions trem pour des codons con-rare et utilisations associees
EP4058006A4 (fr) 2019-11-11 2023-06-28 The Regents Of The University Of California Nanoparticules polymères ciblant des cellules endothéliales sinusoïdales du foie pour induire une tolérance immunitaire spécifique à l'antigène
US20230040275A1 (en) * 2019-11-19 2023-02-09 Spark Therapeutics, Inc. Secretable protein induced immune tolerization and treatment of autoimmune, allergic and other diseases and disorders
US20230036793A1 (en) * 2019-12-12 2023-02-02 Iltoo Pharma Interleukin 2 chimeric constructs
TW202142689A (zh) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 用於轉譯之組合物及其使用方法
CN115279415A (zh) 2020-01-29 2022-11-01 旗舰创业创新第六有限责任公司 用于蛋白调节的包含线性多核糖核苷酸的组合物及其用途
EP4096681A1 (fr) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Administration de compositions comprenant des polyribonucléotides circulaires
EP4103696A1 (fr) 2020-02-10 2022-12-21 Rubius Therapeutics, Inc. Cellules érythroïdes modifiées comprenant des polypeptides hla-g et leurs procédés d'utilisation
US20230210978A1 (en) * 2020-04-02 2023-07-06 Francois Binette A universal adoptive immunotherapy approach to treat covid-19 and future emerging infectious diseases
WO2021211326A1 (fr) * 2020-04-16 2021-10-21 Ix Layer Inc. Systèmes et procédés de gestion d'accès et de regroupement de données génomiques, phénotypiques et de diagnostic
WO2021236952A1 (fr) 2020-05-20 2021-11-25 Flagship Pioneering, Inc. Compositions et procédés de production d'anticorps polyclonaux humains
AU2021275223A1 (en) 2020-05-20 2023-02-02 Flagship Pioneering Innovations Vi, Llc. Coronavirus antigen compositions and their uses
IL298363A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
EP4158032A2 (fr) 2020-05-29 2023-04-05 Flagship Pioneering Innovations VI, LLC Compositions à base de trem et procédés associés
US20230203510A1 (en) 2020-05-29 2023-06-29 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
RU2743363C1 (ru) * 2020-06-03 2021-02-17 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Способ тестирования иммунологической толерантности у животных
WO2021257480A2 (fr) 2020-06-14 2021-12-23 Catalyst Biosciences, Inc. Compositions et procédés associés au facteur i du complément
EP4167984A1 (fr) 2020-06-23 2023-04-26 Flagship Pioneering, Inc. Composés antiviraux et leurs procédés d'utilisation
WO2022005996A1 (fr) * 2020-06-29 2022-01-06 Memorial Sloan Kettering Cancer Center SYSTÈMES POUR SURVEILLER IN VIVO DES CELLULES IMMUNITAIRES CHEZ DES PATIENTS SUBISSANT UNE IMMUNOTHÉRAPIE CELLULAIRE<i />
WO2022005991A1 (fr) * 2020-06-29 2022-01-06 Memorial Sloan Kettering Cancer Center Plate-forme pour évaluer in vivo et in vitro la capture d'haptène dans un système lié à une cellule
EP4189070A1 (fr) * 2020-07-27 2023-06-07 Commissariat à l'Energie Atomique et aux Energies Alternatives Nouveaux lymphocytes t et leurs utilisations
CN112156111B (zh) * 2020-08-31 2022-10-18 中南大学湘雅三医院 脐血血小板线粒体在制备治疗自身免疫疾病药物中的应用
IL300947A (en) 2020-09-03 2023-04-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
KR20230165746A (ko) 2020-11-30 2023-12-05 민데라 코포레이션 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이
CN112544989A (zh) * 2020-12-18 2021-03-26 完美(广东)日用品有限公司 一种具有肌肉保护作用的组合物
KR20230135585A (ko) 2020-12-23 2023-09-25 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 변형된 trem의 조성물 및 이의 용도
JP2024503277A (ja) * 2020-12-29 2024-01-25 スクイーズ バイオテクノロジーズ カンパニー 活性化抗原担体の製剤
RU2766780C1 (ru) * 2020-12-30 2022-03-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Способ определения антигенной нагрузки животных
TW202241471A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 提高個體中NKp30陽性淋巴球的方法及其用途
TW202241470A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 治療人類個體腫瘤之方法
TW202304482A (zh) 2021-03-14 2023-02-01 美商盧比亞斯治療公司 於個體中增加nkg2d陽性淋巴球之方法及其用途
EP4313109A1 (fr) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療hpv16-陽性或hpv16-相關的癌症之方法
GB202108585D0 (en) 2021-06-16 2021-07-28 Rockend Ltd Methods and compositions
WO2023009547A1 (fr) 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Compositions de trem et leurs utilisations
AR127073A1 (es) 2021-09-17 2023-12-13 Flagship Pioneering Innovations Vi Llc Composiciones y métodos para producir polirribonucleótidos circulares
EP4419706A1 (fr) 2021-10-18 2024-08-28 Flagship Pioneering Innovations VI, LLC Compositions et procédés de purification de polyribonucléotides
MX2024006407A (es) 2021-11-24 2024-08-19 Flagship Pioneering Innovations Vi Llc Composiciones de inmunogenos del virus varicela-zoster y sus usos.
WO2023096990A1 (fr) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Compositions immunogènes de coronavirus et leurs utilisations
IL312965A (en) 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and their uses
EP4453201A1 (fr) 2021-12-22 2024-10-30 Flagship Pioneering Innovations VI, LLC Compositions et procédés de purification de polyribonucléotides
AU2022420620A1 (en) 2021-12-23 2024-07-04 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2023164466A1 (fr) * 2022-02-23 2023-08-31 Sqz Biotechnologies Company Procédés de production de cellules gliales et leurs utilisations
WO2023220083A1 (fr) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Compositions de trem et procédés d'utilisation pour traiter des troubles prolifératifs
JP2025516638A (ja) 2022-05-13 2025-05-30 フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー 二本鎖dna組成物及び関連する方法
CN119563038A (zh) 2022-05-25 2025-03-04 旗舰创业创新七公司 用于调节免疫应答的组合物和方法
KR20250019772A (ko) 2022-05-25 2025-02-11 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 종양 억제인자 및 발암유전자를 조절하기 위한 조성물 및 방법
AU2023275550A1 (en) 2022-05-25 2024-11-21 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating cytokines
AU2023277636A1 (en) 2022-05-25 2024-11-21 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating genetic drivers
EP4650780A3 (fr) 2022-05-25 2026-01-21 Flagship Pioneering Innovations VII, LLC Compositions et procédés pour moduler des facteurs circulants
WO2023240274A1 (fr) * 2022-06-10 2023-12-14 The Medical College Of Wisconsin, Inc. Induction d'une tolérance immunitaire pour des maladies auto-immunes par thérapie génique ciblant les plaquettes impliquant un polypeptide de glycoprotéine des oligodendrocytes de la myéline (mog)
EP4544043A1 (fr) 2022-06-22 2025-04-30 Flagship Pioneering Innovations VI, LLC Compositions de trem modifiées et leurs utilisations
CN115381950B (zh) * 2022-09-06 2023-08-18 天津医科大学总医院 Rab 35或其下游调控分子在治疗骨折后慢性疼痛中的应用
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer
EP4612296A1 (fr) 2022-10-31 2025-09-10 Flagship Pioneering Innovations VI, LLC Compositions et procédés de purification de polyribonucléotides
WO2024102799A1 (fr) 2022-11-08 2024-05-16 Flagship Pioneering Innovations Vi, Llc Compositions et procédés de production de polyribonucléotides circulaires
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任(Vii)公司 用於將治療劑遞送至骨之組成物和方法
WO2024148139A2 (fr) * 2023-01-05 2024-07-11 Arizona Board Of Regents On Behalf Of Arizona State University Particules à base de métabolite et compositions associées pour prévenir et traiter des maladies et des troubles neurologiques
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
WO2024151687A1 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Commutateurs génétiques et leur utilisation dans le traitement du cancer
US20240238473A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
KR20250151437A (ko) 2023-02-17 2025-10-21 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 변형된 우라실을 포함하는 dna 조성물
TW202446956A (zh) 2023-02-17 2024-12-01 美商旗艦先鋒創新有限責任(Vii)公司 包含經修飾的胞嘧啶的dna組成物
EP4680276A1 (fr) 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Compositions immunogènes et leurs utilisations
EP4680750A1 (fr) 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Compositions comprenant des polyribonucléotides et leurs utilisations
WO2024216128A1 (fr) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Trems destinés à être utilisés dans la correction de mutations faux-sens
WO2025006684A1 (fr) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Polyribonucléotides circulaires codant pour des polypeptides antifusogènes
WO2025042786A1 (fr) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprenant des polyribonucléotides circulaires et leurs utilisations
WO2025096807A2 (fr) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Nouvelles formes d'adn thérapeutique
US20260000702A1 (en) 2024-06-26 2026-01-01 Flagship Pioneering Innovations Vii, Llc Therapeutic circular dna forms
WO2026055543A1 (fr) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Compositions d'adn modifiées et procédés associés
WO2026055547A1 (fr) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Compositions d'adn et procédés associés
WO2026064313A1 (fr) 2024-09-17 2026-03-26 Flagship Pioneering Innovations Vii, Llc Compositions d'arn et procédés associés
WO2026102108A1 (fr) 2024-11-07 2026-05-15 Flagship Pioneering Innovations Vii, Llc Procédés de production d'adn
WO2026148005A1 (fr) 2025-01-03 2026-07-09 Sail Biomedicines, Inc. Compositions et procédés de purification de polyribonucléotides
WO2026151879A1 (fr) 2025-01-10 2026-07-16 Flagship Pioneering Innovations Vii, Llc Compositions vaccinales et méthodes
WO2026152164A1 (fr) 2025-01-13 2026-07-16 Sail Biomedicines, Inc. Nanoparticules lipidiques ciblant cd5 encapsulant des polyribonucléotides codant pour des récepteurs antigéniques chimériques, et méthodes de génération in vivo de lymphocytes t exprimant un récepteur antigénique chimérique

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327710A (en) 1980-06-18 1982-05-04 The United States Of America As Represented By The Secretary Of Agriculture Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system
IL86650A0 (en) 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
IT1245867B (it) 1991-06-03 1994-10-25 Consiglio Nazionale Ricerche Vaccini utilizzanti eritrociti come veicoli di antigeni
ATE157879T1 (de) 1991-06-14 1997-09-15 Europ Communities Transformierte erythrozyten, verfahren zu deren herstellung, und ihre verwendung in pharmazeutischen zusammensetzungen
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5599705A (en) 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
US6984379B1 (en) 1994-04-08 2006-01-10 Children's Hospital of LosAngeles Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5648248A (en) 1994-12-30 1997-07-15 Boehringer Ingelheim International Gmbh Methods for producing differentiated cells from immature hematopoietic cells
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
WO1998016201A1 (fr) 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Composition de liposomes therapeutiques et procede
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
WO1998021944A1 (fr) 1996-11-21 1998-05-28 New York Blood Center Methode pour convertir le type sanguin
EP0882448B1 (fr) 1997-05-05 2005-01-12 DIDECO S.r.l. Méthode d'encapsulation d'agents biologiquement actifs dans des erythrocytes et appareil
WO1999067360A2 (fr) 1998-06-25 1999-12-29 Hemosol Inc. Culture efficace de cellules souches permettant la production d'hemoglobine
WO2007143451A2 (fr) 2006-05-30 2007-12-13 Terman David S Érythrocytes falciformes, cellules précurseurs nucléés et cellules érythroleucémiques pour la délivrance ciblée de virus oncolytiques, protéines antitumorales, plasmides, toxines, hémolysines et agents chimiothérapeutiques
US7767202B2 (en) 2001-03-16 2010-08-03 The Johns Hopkins University Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
US20030207247A1 (en) 2001-12-05 2003-11-06 Cerus Corporation Preparation of red blood cells having reduced immunogenicity
US20030133922A1 (en) 2002-01-15 2003-07-17 Kasha John R. Oral tolerance using allogeneic platelets in ITP
US7427603B2 (en) 2002-09-26 2008-09-23 The Children's Medical Center Corporation Method of enhancing proliferation and/or hematopoietic differentiation of stem cells
JP4069730B2 (ja) * 2002-11-27 2008-04-02 株式会社日立製作所 受信装置、印刷装置および印刷制御方法
WO2004050859A2 (fr) 2002-11-27 2004-06-17 Regents Of The University Of Minnesota Recombinaison homologue dans des cellules souches adultes multipotentes
ES2348868T3 (es) 2002-12-13 2010-12-16 Genetix Pharmaceuticals Inc. Vectores retrovirales terapeuticos para terapia genica.
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
CA2566561C (fr) 2004-06-04 2013-01-08 Universite Pierre Et Marie Curie - Paris Vi Methode de production de globules rouges
CA2574802A1 (fr) * 2004-07-20 2006-02-02 Isogenis, Inc. Inhibition specifique d'auto-immunite et maladies associees a des auto-antigenes
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
DE102004054536A1 (de) 2004-11-06 2006-05-11 Capsulution Nanoscience Ag Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel
FR2884717B1 (fr) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
SG10202001007TA (en) * 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
FR2891843A1 (fr) 2005-10-06 2007-04-13 Erytech Pharma Soc Par Actions Erythrocytes contenant du 5-fluorouracile
US7462485B2 (en) 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
US20070243137A1 (en) 2006-04-18 2007-10-18 Nanoprobes, Inc. Cell and sub-cell methods for imaging and therapy
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
EP2012122A1 (fr) * 2007-07-06 2009-01-07 Medigene AG Protéines structurelles de parvovirus muté
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US9260692B2 (en) 2007-10-31 2016-02-16 Universitat Zurich Use of modified cells for the treatment of multiple sclerosis
EP2057998A1 (fr) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Utilisation de cellules modifiées dans le traitement de la sclérose en plaques
FR2925339B1 (fr) 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
ES2405258T3 (es) 2008-02-13 2013-05-30 Erytech Pharma Formulación y procedimiento para la prevención y el tratamiento de la manifestación esquelética de la enfermedad de Gaucher
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
US8231895B2 (en) 2008-05-22 2012-07-31 Universidade De Coimbra Targeted delivery to human diseases and disorders
US20110070154A1 (en) * 2008-08-13 2011-03-24 Hyde Roderick A Artificial cells
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20100040546A1 (en) 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
FR2938332B1 (fr) 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
EA201100765A1 (ru) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
FR2944106B1 (fr) 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
AU2010235161B2 (en) 2009-04-09 2015-01-22 Sangamo Therapeutics, Inc. Targeted integration into stem cells
EP2432496B1 (fr) 2009-05-19 2018-03-28 ETH Zurich Régulation de l'homéostasie de l'acide urique
ES2600932T3 (es) 2009-10-27 2017-02-13 Erytech Pharma Composición para inducir una tolerancia inmunitaria específica
MX2012009942A (es) * 2010-03-02 2012-09-21 Hoffmann La Roche Vector de expresion.
WO2011112883A1 (fr) 2010-03-12 2011-09-15 The Regents Of The University Of California Libération déclenchée de la cargaison de liposomes nanoparticulaires stabilisés
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN101985634B (zh) * 2010-11-04 2012-06-13 中国人民解放军第四军医大学 一种gfp膜型表达的载体及转染该载体的阳性细胞的分选方法
CN102199199A (zh) * 2011-04-06 2011-09-28 中国人民解放军第四军医大学 膜定位葡萄球菌肠毒素a及其基因序列
WO2013059343A1 (fr) 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Administration intracellulaire
CA2864432A1 (fr) 2012-02-15 2013-08-22 Ecole Polytechnique Federale De Lausanne Agents therapeutiques se liant aux erythrocytes
US20150118265A1 (en) 2012-03-13 2015-04-30 Anthrogenesis Corporation Modified erythrocyte precursor cells and uses thereof
US20150086521A1 (en) 2012-03-21 2015-03-26 Erytech Pharma Medicament for the Treatment of Acute Myeloid Leukemia (AML)
EP2669381A1 (fr) 2012-05-30 2013-12-04 AmVac AG Procédé pour l'expression de protéines hétérologues à l'aide d'un vecteur de virus recombinant à ARN négatifs comprenant une P proteine mutante
US8975072B2 (en) 2012-07-20 2015-03-10 Riken Human erythroid progenitor cell line comprising HPV E6/E7 operably linked to an inducible promoter and method for producing human enucleated red blood cells
EP2914274A4 (fr) 2012-11-01 2016-07-20 Sydney Children S Hospital Network Randwick And Westmead Probiotique modifié génétiquement pour le traitement de la phénylcétonurie
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
CN103224957B (zh) * 2013-04-16 2017-08-04 福建三一造血技术有限公司 体外诱导生成含L‑ASPase II的红细胞药物的方法
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
CN105228596B (zh) 2013-05-10 2018-08-24 爱瑞德勒股份有限公司 用于制备载有一种或多种制药学感兴趣物质的红细胞的方法和由此得到的红细胞
EP3693398A1 (fr) 2013-05-10 2020-08-12 Whitehead Institute for Biomedical Research Production in vitro de globules rouges avec des protéines pouvant être médiée par une sortase
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
EP2813234A1 (fr) 2013-06-11 2014-12-17 Erytech Pharma Composition d'érythrocytes encapsulant phenylalanine hydroxylase et l'emploi thérapeutique
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
EP3882259B1 (fr) 2015-05-13 2026-01-28 Synlogic Operating Company, Inc. Bactéries conçues pour réduire l'hyperphénylalaninémie
WO2016183482A1 (fr) 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Agents thérapeutiques d'un complexe membrane-récepteur
EP3187190A1 (fr) 2015-12-31 2017-07-05 Erytech Pharma Procédé de traitement d'un mammifère, y compris l'être humain, contre le cancer au moyen de la méthionine et la déplétion de l'asparagine
CN108697733A (zh) 2016-01-11 2018-10-23 鲁比厄斯治疗法股份有限公司 与癌症适应症的多模式治疗性细胞体系有关的组合物和方法
MX2019000205A (es) 2016-07-07 2019-09-23 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
BR112019011138A2 (pt) 2016-12-02 2019-10-01 Rubius Therapeutics, Inc. composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos
CN110520522A (zh) 2017-02-17 2019-11-29 鲁比厄斯治疗法股份有限公司 功能化红系细胞
EP3672602A1 (fr) 2017-08-22 2020-07-01 Rubius Therapeutics, Inc. Procédés et compositions de nanoparticules lipidiques destinés à la production de cellules érythroïdes modifiées
WO2019090148A2 (fr) 2017-11-03 2019-05-09 Rubius Therapeutics, Inc. Compositions et procédés associés à des systèmes cellulaires thérapeutiques pour inhiber la croissance tumorale
US20190201548A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for engineering erythroid cells
WO2019140116A2 (fr) 2018-01-10 2019-07-18 Rubius Therapeutics, Inc. Arn amplifiables pour systèmes cellulaires thérapeutiques

Also Published As

Publication number Publication date
BR112016022814A2 (pt) 2017-08-15
HUE054471T2 (hu) 2021-09-28
ES2865825T3 (es) 2021-10-18
US20170020926A1 (en) 2017-01-26
IL278643B (en) 2021-08-31
RU2016142671A (ru) 2018-05-10
BR112016022814A8 (pt) 2021-07-06
PT3125927T (pt) 2021-04-30
US20190247440A1 (en) 2019-08-15
KR20220150986A (ko) 2022-11-11
AU2015241422B2 (en) 2020-12-03
US11576934B2 (en) 2023-02-14
CA2944492A1 (fr) 2015-10-08
KR20170005801A (ko) 2017-01-16
IL285565A (en) 2021-09-30
JP6735233B2 (ja) 2020-08-05
US10869898B2 (en) 2020-12-22
JP2017517485A (ja) 2017-06-29
IL248143A0 (en) 2016-11-30
RU2016142671A3 (fr) 2018-11-01
JP2023052281A (ja) 2023-04-11
WO2015153102A1 (fr) 2015-10-08
DK3125927T3 (da) 2021-04-19
EP3583946A1 (fr) 2019-12-25
AU2019208203A1 (en) 2019-08-08
MX2020000621A (es) 2020-11-12
AU2015241422A1 (en) 2016-10-27
CN106456744A (zh) 2017-02-22
IL285565B (en) 2022-04-01
JP2021102649A (ja) 2021-07-15
EP3125927B1 (fr) 2021-01-27
AU2021232711A1 (en) 2021-10-14
PL3125927T3 (pl) 2021-07-19
EP3125927A1 (fr) 2017-02-08
RU2736495C2 (ru) 2020-11-17
AU2019208203B2 (en) 2021-06-17
US20190388473A1 (en) 2019-12-26
JP6865253B2 (ja) 2021-04-28
US20180271910A1 (en) 2018-09-27
JP2019206573A (ja) 2019-12-05
RU2020136119A (ru) 2021-05-17
US11554141B2 (en) 2023-01-17
IL248143B (en) 2020-08-31

Similar Documents

Publication Publication Date Title
MX2020000621A (es) Composiciones para usarse en inmunomodulacion.
PH12019500627A1 (en) Affinity-oligonucleotide conjugates and uses thereof
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
IL251576A0 (en) Methods and compositions for creating or maintaining multifunctional cells
IL251951A0 (en) Methods and compositions for natural killer cells
EP3212225A4 (fr) Procédés et compositions permettant l&#39;obtention de lymphocytes t modifiés
TW201613966A (en) SynTac polypeptides and uses thereof
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
IL249828A0 (en) Limbal stem cells of cultured mammals, methods of their creation and uses thereof
GB201611982D0 (en) Cell culture
SG10201810150UA (en) Compositions and methods for enhanced gene expression in cone cells
EP3240552A4 (fr) Cellules tueuses naturelles et leurs utilisations
PT3151672T (pt) Composições de células t melhoradas
EP3215139A4 (fr) Compositions et procédés pour thérapies par cellules car-t améliorées
EP3224349A4 (fr) Procédé de culture de cellules tueuses naturelles à l&#39;aide de lymphocytes t
EP3196287A4 (fr) Appareil de culture de cellules
EP3235900A4 (fr) Appareil de culture cellulaire
SG11201701237QA (en) Compositions for modulating cancer stem cells and uses therefor
SG11202004935UA (en) Cell culture methods
EP3198007A4 (fr) Méthodes et compositions pour moduler la fonction d&#39;un lymphocyte th-gm auxiliaire
PL3287521T3 (pl) Hodowla komórkowa
HUE066922T2 (hu) Sejttenyésztési eljárások
MX371121B (es) Composiciones para usarse en inmunomodulación.
GB201608764D0 (en) Novel cell culture
HK1233539A1 (en) Methods and compositions for immunomodulation